- Home
- EWTX vs EVT Comparison
EWTX vs EVT Comparison
Compare EWTX & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- EVT
- Stock Information
- Founded
- EWTX 2017
- EVT 2003
- Country
- EWTX United States
- EVT United States
- Employees
- EWTX N/A
- EVT N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- EVT Finance Companies
- Sector
- EWTX Health Care
- EVT Finance
- Exchange
- EWTX Nasdaq
- EVT Nasdaq
- Market Cap
- EWTX 1.5B
- EVT 1.7B
- IPO Year
- EWTX 2021
- EVT N/A
- Fundamental
- Price
- EWTX $13.93
- EVT $24.34
- Analyst Decision
- EWTX Buy
- EVT
- Analyst Count
- EWTX 8
- EVT 0
- Target Price
- EWTX $41.13
- EVT N/A
- AVG Volume (30 Days)
- EWTX 633.0K
- EVT 115.5K
- Earning Date
- EWTX 08-07-2025
- EVT 01-01-0001
- Dividend Yield
- EWTX N/A
- EVT 8.32%
- EPS Growth
- EWTX N/A
- EVT N/A
- EPS
- EWTX N/A
- EVT 6.63
- Revenue
- EWTX N/A
- EVT $69,404,302.00
- Revenue This Year
- EWTX N/A
- EVT N/A
- Revenue Next Year
- EWTX N/A
- EVT N/A
- P/E Ratio
- EWTX N/A
- EVT $3.55
- Revenue Growth
- EWTX N/A
- EVT N/A
- 52 Week Low
- EWTX $10.60
- EVT $19.20
- 52 Week High
- EWTX $38.12
- EVT $25.83
- Technical
- Relative Strength Index (RSI)
- EWTX 52.63
- EVT 59.54
- Support Level
- EWTX $12.30
- EVT $23.73
- Resistance Level
- EWTX $14.11
- EVT $24.27
- Average True Range (ATR)
- EWTX 0.73
- EVT 0.23
- MACD
- EWTX 0.00
- EVT 0.02
- Stochastic Oscillator
- EWTX 53.80
- EVT 87.95
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.